The abstract is read at the publisher; the summary is JClub's.
In early-stage mismatch repair-deficient solid tumors after curative resection, ctDNA-guided pembrolizumab achieved 85% ctDNA clearance at 6 months in MRD-positive patients.
- Why it matters: MRD-positive dMMR patients after surgery face high recurrence risk, yet few studies show whether intervening based on ctDNA can change outcomes.
- What they did: In a prospective phase II study, ctDNA mutations were matched to somatic mutations from resected tumors to confirm MRD, then confirmed MRD-positive patients received 6 months of PD-1 blockade.
- The result: Among 13 treated MRD-positive patients, 38% developed recurrence during follow-up, while 2-year recurrence-free survival was 92% in 152 MRD-negative patients under observation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.